With over 25 years of sales and marketing experience in the high tech industry, Mr. Pharisien has developed a strong track record for driving significant revenue growth, cultivating strong customer relationships and developing successful strategic business partnerships. "We are pleased to welcome Rene to DecisionView and the executive management team. His experience in building and leading high performance sales organizations in high growth technology companies will be a tremendous asset to the company," said Steve Andrade, CEO of DecisionView.
Rene began his technology sales career with Prime Computer where he quickly rose through the ranks becoming one of the youngest managers in the company''s history. He subsequently held key posts at several leading technology companies including Siebel Systems, Sequent and 3Com. Most recently Mr. Pharisien was Senior Vice President of Worldwide Sales at Kintera, a "Software-as-a-Service" company and previously held executive management positions with Niku as Vice President of Marketing and at Epiphany where he was Western Area Vice President of Sales.
"I am delighted to join DecisionView and look forward to executing on the company''s compelling vision and strategy. The clinical trial process is mission critical for life sciences companies and managing that process effectively is a key component in reducing costs and improving effectiveness in the healthcare industry," said Rene Pharisien. "StudyOptimizer(TM) is a revolutionary software solution that is at the nexus of solving one of the biggest challenges faced by pharmaceutical and biotechnology companies- bringing new therapies to market faster and more cost effectively," Pharisien continued.
DecisionView develops innovative web-based software solutions that enable life sciences organizations around the world to improve clinical trial performance. DecisionView helps organizations make informed decisions by aggregating data from multiple sources and providing analytics, simulations and scenario modeling that deliver proven business value by reducing clinical trial costs and improving clinical trial predictability. Granite Ventures, Partech International and first Ventury are primary investors in the company.
Additional information about DecisionView can be found at
Source: DecisionView Inc.